EA200000325A1 - Способ доставки генов в антиген-презентирующие клетки кожи - Google Patents
Способ доставки генов в антиген-презентирующие клетки кожиInfo
- Publication number
- EA200000325A1 EA200000325A1 EA200000325A EA200000325A EA200000325A1 EA 200000325 A1 EA200000325 A1 EA 200000325A1 EA 200000325 A EA200000325 A EA 200000325A EA 200000325 A EA200000325 A EA 200000325A EA 200000325 A1 EA200000325 A1 EA 200000325A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antigen
- delivery
- presentating
- genes
- skin cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 210000004927 skin cell Anatomy 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108700005077 Viral Genes Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000008260 defense mechanism Effects 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Молекулярный поставочный комплекс, специфичный в отношении антиген-презентирующих клеток, формируется на основе невирусной генной поставочной системы, к которой добавляется чужеродный генетический материал. Сформированный комплекс затем проникает в клетки-мишени опосредованно через специфический рецептор и преодолевает защитные механизмы, в результате чего проникновение чужеродного генетического материала или его трансдукция приводят к экспрессии гена. Также настоящее изобретение представляет способ генетической иммунизации без инъекций.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5893397P | 1997-09-15 | 1997-09-15 | |
PCT/US1998/019498 WO1999013915A1 (en) | 1997-09-15 | 1998-09-15 | Method of delivering genes to antigen presenting cells of the skin |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200000325A1 true EA200000325A1 (ru) | 2000-10-30 |
EA003832B1 EA003832B1 (ru) | 2003-10-30 |
Family
ID=22019811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200000325A EA003832B1 (ru) | 1997-09-15 | 1998-09-15 | Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования |
Country Status (18)
Country | Link |
---|---|
US (2) | US6420176B1 (ru) |
EP (1) | EP1024836B1 (ru) |
JP (1) | JP2001516729A (ru) |
KR (1) | KR100615117B1 (ru) |
CN (1) | CN100391542C (ru) |
AP (1) | AP1427A (ru) |
AT (1) | ATE347911T1 (ru) |
AU (1) | AU754425B2 (ru) |
BR (1) | BR9813202B1 (ru) |
CA (1) | CA2302316A1 (ru) |
DE (1) | DE69836643T2 (ru) |
EA (1) | EA003832B1 (ru) |
ES (1) | ES2279580T3 (ru) |
IL (2) | IL134842A0 (ru) |
NO (1) | NO327491B1 (ru) |
NZ (1) | NZ503334A (ru) |
OA (1) | OA11612A (ru) |
WO (1) | WO1999013915A1 (ru) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
AU754425B2 (en) * | 1997-09-15 | 2002-11-14 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
US20020006412A1 (en) * | 2000-04-28 | 2002-01-17 | Roberts Bruce L. | Preparation and use of particulates composed of adenovirus particles |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
BR122012021252B8 (pt) * | 2002-09-06 | 2021-05-25 | Cerulean Pharma Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
CN1717209A (zh) * | 2002-10-09 | 2006-01-04 | 植入疗法公司 | 以环糊精为基础的材料、其相关的组合物和用途 |
EP1590432A4 (en) | 2003-01-15 | 2008-05-14 | Res Inst For Genetic And Human | DNA COMPOSITION AND ITS USE |
WO2005056749A2 (en) * | 2003-12-09 | 2005-06-23 | Engeneic Molecular Delivery Pty Ltd. | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
EP2722387B1 (en) | 2003-12-23 | 2019-12-11 | Viacyte, Inc. | Definitive endoderm |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
US8586357B2 (en) | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
EP2377922B1 (en) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
WO2006016999A1 (en) | 2004-07-09 | 2006-02-16 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
CA2576872C (en) | 2004-08-13 | 2013-11-12 | University Of Georgia Research Foundation, Inc. | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
AU2005284727A1 (en) * | 2004-09-17 | 2006-03-23 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
KR20060073172A (ko) | 2004-12-24 | 2006-06-28 | 재단법인서울대학교산학협력재단 | 생체 고분자/유전자 복합체 |
BRPI0501037B8 (pt) * | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | uso de crotamina e composição |
WO2007050643A2 (en) * | 2005-10-24 | 2007-05-03 | University Of Massachusetts | Compositions and their uses for gene therapy of bone conditions |
DK2674485T3 (da) | 2005-10-27 | 2019-08-26 | Viacyte Inc | Pdx-1 udtrykkende dorsal og ventral fortarm endoderm |
US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
SG10201405380QA (en) | 2006-03-02 | 2014-10-30 | Cythera Inc | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
WO2007127454A2 (en) | 2006-04-28 | 2007-11-08 | Cythera, Inc. | Hepatocyte lineage cells |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
CA2704056A1 (en) * | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
AU2008323811B8 (en) | 2007-11-08 | 2014-09-18 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
WO2010008582A2 (en) * | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
CN102282254B (zh) | 2008-11-14 | 2015-12-16 | 维赛特公司 | 源于人多能干细胞的胰腺细胞的包封 |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
HU0900117D0 (en) | 2009-02-26 | 2009-04-28 | Genetic Immunity Kutatasi | Topical or transdermal delivery kit |
EP2453911A1 (en) * | 2009-04-30 | 2012-05-23 | Genetic Immunity Kft | Immunogenic nanomedicine composition and preparation and uses thereof |
JP6220126B2 (ja) * | 2009-11-23 | 2017-10-25 | セルリアン・ファーマ・インコーポレイテッド | 治療的送達のためのシクロデキストリンに基づく重合体 |
WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
RS57439B1 (sr) * | 2010-06-22 | 2018-09-28 | Onxeo | Optimizovani sistem sa endosomolitičkim agensima za in vivo primenu konjugata nukleinskih kiselina |
CN102146416B (zh) * | 2010-12-30 | 2013-03-13 | 江苏大学 | 阳离子化杏鲍菇多糖纳米粒基因传递系统及其制法 |
EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
EP3033108B1 (en) | 2013-08-16 | 2021-03-24 | University Of Rochester | Designed peptides for tight junction barrier modulation |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
ES2742197T7 (es) | 2015-07-23 | 2021-10-06 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
CN105396140B (zh) * | 2015-12-02 | 2019-07-02 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
US20220249364A1 (en) | 2019-06-05 | 2022-08-11 | University Of Rochester | Designed Inhibitors of Tight Junction Formation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
AU2242799A (en) * | 1994-02-22 | 1999-05-27 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
WO1996004386A1 (en) * | 1994-08-05 | 1996-02-15 | Warner-Lambert Company | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
CA2223921A1 (en) * | 1995-06-07 | 1996-12-19 | Francis C. Szoka, Jr. | Stabilization of polynucleotide complexes |
DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
CA2246359A1 (en) * | 1996-02-21 | 1997-08-28 | Julianna Lisziewicz | Methods and compositions for protective and therapeutic genetic immunization |
FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
AU754425B2 (en) * | 1997-09-15 | 2002-11-14 | Genetic Immunity, Llc. | Method of delivering genes to antigen presenting cells of the skin |
-
1998
- 1998-09-15 AU AU93980/98A patent/AU754425B2/en not_active Ceased
- 1998-09-15 IL IL13484298A patent/IL134842A0/xx active IP Right Grant
- 1998-09-15 ES ES98947128T patent/ES2279580T3/es not_active Expired - Lifetime
- 1998-09-15 BR BRPI9813202-4A patent/BR9813202B1/pt not_active IP Right Cessation
- 1998-09-15 CA CA002302316A patent/CA2302316A1/en not_active Abandoned
- 1998-09-15 DE DE69836643T patent/DE69836643T2/de not_active Expired - Lifetime
- 1998-09-15 EP EP98947128A patent/EP1024836B1/en not_active Expired - Lifetime
- 1998-09-15 KR KR1020007002661A patent/KR100615117B1/ko not_active IP Right Cessation
- 1998-09-15 OA OA1200000074A patent/OA11612A/en unknown
- 1998-09-15 AT AT98947128T patent/ATE347911T1/de not_active IP Right Cessation
- 1998-09-15 EA EA200000325A patent/EA003832B1/ru not_active IP Right Cessation
- 1998-09-15 JP JP2000511529A patent/JP2001516729A/ja active Pending
- 1998-09-15 NZ NZ503334A patent/NZ503334A/en unknown
- 1998-09-15 US US09/153,198 patent/US6420176B1/en not_active Expired - Fee Related
- 1998-09-15 CN CNB988111675A patent/CN100391542C/zh not_active Expired - Fee Related
- 1998-09-15 WO PCT/US1998/019498 patent/WO1999013915A1/en active IP Right Grant
- 1998-09-15 AP APAP/P/2000/001762A patent/AP1427A/en active
-
2000
- 2000-03-01 IL IL134842A patent/IL134842A/en not_active IP Right Cessation
- 2000-03-09 NO NO20001244A patent/NO327491B1/no not_active IP Right Cessation
-
2002
- 2002-02-21 US US10/081,922 patent/US7910562B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20020193333A1 (en) | 2002-12-19 |
NO327491B1 (no) | 2009-07-20 |
AP2000001762A0 (en) | 2000-03-31 |
EA003832B1 (ru) | 2003-10-30 |
IL134842A (en) | 2009-02-11 |
US6420176B1 (en) | 2002-07-16 |
JP2001516729A (ja) | 2001-10-02 |
ATE347911T1 (de) | 2007-01-15 |
AP1427A (en) | 2005-06-07 |
NO20001244L (no) | 2000-05-15 |
IL134842A0 (en) | 2001-05-20 |
EP1024836A1 (en) | 2000-08-09 |
BR9813202B1 (pt) | 2011-11-01 |
CN100391542C (zh) | 2008-06-04 |
DE69836643T2 (de) | 2007-09-27 |
CA2302316A1 (en) | 1999-03-25 |
EP1024836A4 (en) | 2003-07-02 |
NO20001244D0 (no) | 2000-03-09 |
OA11612A (en) | 2004-08-13 |
ES2279580T3 (es) | 2007-08-16 |
DE69836643D1 (de) | 2007-01-25 |
CN1278739A (zh) | 2001-01-03 |
WO1999013915A1 (en) | 1999-03-25 |
AU754425B2 (en) | 2002-11-14 |
US7910562B2 (en) | 2011-03-22 |
NZ503334A (en) | 2002-05-31 |
KR20010030598A (ko) | 2001-04-16 |
EP1024836B1 (en) | 2006-12-13 |
AU9398098A (en) | 1999-04-05 |
KR100615117B1 (ko) | 2006-08-22 |
BR9813202A (pt) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200000325A1 (ru) | Способ доставки генов в антиген-презентирующие клетки кожи | |
Pelletier et al. | Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA | |
ATE464067T1 (de) | Bindegewebs wachstumsfaktor (ctgf) | |
FR17C1046I2 (fr) | Nouvelles molecules b7-4 et leurs utilisations | |
GR3026129T3 (en) | Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound. | |
ATE386131T1 (de) | Aav-vermittelte überbringung von dna in zellen des nervensystems | |
ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
FR2711670B1 (fr) | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. | |
RU95115239A (ru) | Аналог эритропоэтина | |
PT920498E (pt) | Adn regulador transcricional de ef-1x de hamster | |
CY1109837T1 (el) | Διαγνωστικο και θεραπευτικο επιτοπιο | |
HUP9700428A2 (hu) | Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása | |
Alvarez et al. | Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences | |
BR9712556A (pt) | Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno | |
RU2218181C2 (ru) | ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ | |
ATE306498T1 (de) | Von zellen präsentierte peptide | |
ATE300619T1 (de) | Humane checkpointkinase, hcds1, zusammensetzungen und verfahren | |
ATE404217T1 (de) | Therapie mit lipoproteinlipase (lpl) variant | |
BR0010155A (pt) | Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo | |
EA200100264A1 (ru) | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly | |
US7008783B1 (en) | Gene encoding chondroitinase ABC and uses therefor | |
DE60140559D1 (de) | 32144, eine humane fettsäureamid-hydrolase und deren verwendungen | |
DE59510829D1 (de) | Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen | |
SE9701228D0 (sv) | Rekombinanta protein-C-och protein-S-varianter | |
DE60137222D1 (de) | Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |